UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden

hours per response:

0.5

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E. 42ND STREET

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

01/29/2014

3. Issuer Name and Ticker or Trading Symbol

Celladon Corp

[ CLDN ]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director

10% Owner

Officer (give title below)

Other (specify below)

5. If Amendment, Date of Original Filed

(Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr.

4)

2.

Amount of Securities Beneficially Owned (Instr.

4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr.

5)

4. Nature of Indirect Beneficial Ownership (Instr.

5)

Table II - Derivative Securities Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.

4)

2. Date Exercisable and Expiration Date

(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr.

4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form: Direct (D) or Indirect (I) (Instr.

5)

6. Nature of Indirect Beneficial Ownership (Instr.

5)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series A-1 Convertible Preferred Stock

(1)

(1)

Common Stock

1,544,397(2)

$0.00(1)

Convertible Promissory Notes

(3)

(3)

Common Stock

$181,818.18

(3)

Series A-1 Preferred Warrants

10/15/2013

10/15/2018

Series A-1 Preferred Stock

532,818(4)

$0.449(4)

Explanation of Responses:

1. The shares of Series A-1 Preferred Stock have no expiration date and are convertible at any time at the election of the holder. Each share of Series A-1 Preferred Stock will automatically convert on a one-for-one basis into shares of common stock upon the closing of the Issuer's initial public offering.

2. Share numbers assume or give effect to the 1-for-12.49 reverse stock split of the Issuer's Common Stock effected on October 25, 2013, which will be effective for the Preferred Stock upon its conversion to Common Stock immediately prior to the closing of the Issuer's initial public offering.

3. Consists of principal, that together with accrued interest, will convert immediately prior to the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price equal to the public offering price of the Common Stock sold in the Issuer's initial public offering.

4. Share numbers and exercise price do not give effect to the 1-for-12.49 reverse stock split of the Issuer's Common Stock effected on October 25, 2013, which will be effective for the Preferred Stock upon its conversion to Common Stock immediately prior to the closing of the Issuer's initial public offering

Remarks:

/s/ Susan Grant, Assistant Secretary on behalf of Pfizer Inc.

01/29/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,

see

Instruction

(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations

See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,

see

Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.